Alzheimer's disease drug development pipeline: 2025
Abstract Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.70098 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850163770208288768 |
|---|---|
| author | Jeffrey L. Cummings Yadi Zhou Garam Lee Kate Zhong Jorge Fonseca Amanda M. Leisgang‐Osse Feixiong Cheng |
| author_facet | Jeffrey L. Cummings Yadi Zhou Garam Lee Kate Zhong Jorge Fonseca Amanda M. Leisgang‐Osse Feixiong Cheng |
| author_sort | Jeffrey L. Cummings |
| collection | DOAJ |
| description | Abstract Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease‐targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the primary outcomes of 27% of active trials. Repurposed agents represent 33% of the pipeline agents. The pipeline has more trials and more drugs compared to the 2024 pipeline. Highlights The 2025 Alzheimer's disease drug development pipeline hosts 182 trials and 138 novel drugs. The 2025 Alzheimer's disease drug development pipeline is diverse, with agents that address 15 basic disease processes. The 2025 Alzheimer's disease drug development pipeline has more trials and more drugs than the 2024 pipeline. Biomarkers play an important role in current trials to determine trial eligibility and as outcomes of trials. Repurposed agents comprise approximately one‐third of the agents and trials in the 2025 Alzheimer's disease drug development pipeline. |
| format | Article |
| id | doaj-art-953f982a843b467c829a372111785c59 |
| institution | OA Journals |
| issn | 2352-8737 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-953f982a843b467c829a372111785c592025-08-20T02:22:09ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372025-04-01112n/an/a10.1002/trc2.70098Alzheimer's disease drug development pipeline: 2025Jeffrey L. Cummings0Yadi Zhou1Garam Lee2Kate Zhong3Jorge Fonseca4Amanda M. Leisgang‐Osse5Feixiong Cheng6Chambers‐Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USAGenomic Medicine Institute Lerner Research Institute, Cleveland Clinic Cleveland Ohio USAChambers‐Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USAChambers‐Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USAHoward R Hughes College of Engineering Department of Computer Science University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USAChambers‐Grundy Center for Transformative Neuroscience Department of Brain Health Kirk Kerkorian School of Medicine University of Nevada, Las Vegas (UNLV) Las Vegas Nevada USAGenomic Medicine Institute Lerner Research Institute, Cleveland Clinic Cleveland Ohio USAAbstract Clinical trials for Alzheimer's disease (AD) must be registered on clinicaltrials.gov. The registry presents a variety of types of information related to the planned clinical trial. We assess clinicaltrials.gov to document and compare aspects of drug development across the AD pipeline. Currently, there are 138 drugs being assessed in 182 clinical trials in the AD pipeline. Biological disease‐targeted therapies (DTTs) comprise 30% of the pipeline; small molecule DTTs account for 43% of the pipeline; drugs addressing cognitive enhancement account for 14% of the pipeline; and drugs aiming to ameliorate neuropsychiatric symptoms in participants with AD contribute 11% of the pipeline. Biomarkers are among the primary outcomes of 27% of active trials. Repurposed agents represent 33% of the pipeline agents. The pipeline has more trials and more drugs compared to the 2024 pipeline. Highlights The 2025 Alzheimer's disease drug development pipeline hosts 182 trials and 138 novel drugs. The 2025 Alzheimer's disease drug development pipeline is diverse, with agents that address 15 basic disease processes. The 2025 Alzheimer's disease drug development pipeline has more trials and more drugs than the 2024 pipeline. Biomarkers play an important role in current trials to determine trial eligibility and as outcomes of trials. Repurposed agents comprise approximately one‐third of the agents and trials in the 2025 Alzheimer's disease drug development pipeline.https://doi.org/10.1002/trc2.70098Alzheimer's diseaseamyloidbiomarkersclinical trialsCommon Alzheimer's Disease Research Ontology (CADRO)drug development |
| spellingShingle | Jeffrey L. Cummings Yadi Zhou Garam Lee Kate Zhong Jorge Fonseca Amanda M. Leisgang‐Osse Feixiong Cheng Alzheimer's disease drug development pipeline: 2025 Alzheimer’s & Dementia: Translational Research & Clinical Interventions Alzheimer's disease amyloid biomarkers clinical trials Common Alzheimer's Disease Research Ontology (CADRO) drug development |
| title | Alzheimer's disease drug development pipeline: 2025 |
| title_full | Alzheimer's disease drug development pipeline: 2025 |
| title_fullStr | Alzheimer's disease drug development pipeline: 2025 |
| title_full_unstemmed | Alzheimer's disease drug development pipeline: 2025 |
| title_short | Alzheimer's disease drug development pipeline: 2025 |
| title_sort | alzheimer s disease drug development pipeline 2025 |
| topic | Alzheimer's disease amyloid biomarkers clinical trials Common Alzheimer's Disease Research Ontology (CADRO) drug development |
| url | https://doi.org/10.1002/trc2.70098 |
| work_keys_str_mv | AT jeffreylcummings alzheimersdiseasedrugdevelopmentpipeline2025 AT yadizhou alzheimersdiseasedrugdevelopmentpipeline2025 AT garamlee alzheimersdiseasedrugdevelopmentpipeline2025 AT katezhong alzheimersdiseasedrugdevelopmentpipeline2025 AT jorgefonseca alzheimersdiseasedrugdevelopmentpipeline2025 AT amandamleisgangosse alzheimersdiseasedrugdevelopmentpipeline2025 AT feixiongcheng alzheimersdiseasedrugdevelopmentpipeline2025 |